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BRIEF COMMUNICATION
HEPATITIS C VIRUS GENOTYPES IN HEMODIALYSIS PATIENTS IN THE FEDERAL DISTRICT, BRAZIL
Regina M.S. AMORIM(1), Tainá RAIOL(1), José E. TREVIZOLI(2), Francisco A. R. NEVES(2), Cláudia R.F. MARTINS(1) & Regina M.B. MARTINS(3)
SUMMARY
Hepatitis C virus (HCV) genotypes and subtypes were determined in hemodialysis patients in the Federal District, Brazil, by 
sequencing of the 5’ noncoding (NC) and nonstructural 5B (NS5B) regions. From 761 patients, 66 anti-HCV-positive samples were 
tested for HCV RNA. All 51 HCV RNA-positive samples by PCR of the 5’ NC region were genotyped as genotypes 1 (90.2%) and 3 
(9.8%). Subtype 1a (82.3%) was the most prevalent, followed by subtypes 3a (9.8%), 1b (5.9%) and 1a/1b (2.0%). Forty-two samples 
could be amplif﻿﻿ied and genotyped in the NS5B region: 38 (90.5%) as genotype 1, subtypes 1a, and 8 (9.5%) as genotype 3, subtype 
3a. For the 42 samples sequenced in both regions, the genotypes and subtypes determined were concordant in 100% and 95.2% of 
cases, respectively. Two samples presented discrepant results, with the 5’ NC region not distinguishing correctly the subtypes 1a and 
1b. These f﻿﻿indings indicate that the HCV genotype 1, subtype 1a, is the most prevalent among hemodialysis patients in the Federal 
District, Brazil.
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INTRODUCTION
Hemodialysis patients are at high risk of acquiring the hepatitis C 
virus (HCV) infection. These patients have an increased tendency to 
become HCV chronic carriers and also to be a potential reservoir for its 
transmission, possibly contributing to the nosocomial spread of HCV in 
dialysis centers5,13. In addition, hepatitis C seems to increase the mortality 
rate in this group of patients4,20. 
Based on the nucleotide (nt) sequence divergence, HCV is classif﻿﻿ied 
into six major genetic groups, designated genotypes (1 to 6), each one 
comprising multiple subtypes (designated a, b, c, etc). These genotypes 
and subtypes have distinct geographical distributions. Genotype 
determination is a relevant predictive parameter of the response to the 
antiviral treatment. Information about subtype distribution is required to 
perform effective HCV molecular and epidemiological surveillance, to 
study modes of transmission, and improve further vaccine development 
efforts22.
In order to determine HCV genotypes and subtypes, the choice of 
the genome region to be analyzed is crucial. This region must present 
genotype-specif﻿﻿ic and subtype-specif﻿﻿ic motifs. Additionally it must be 
highly conserved to be detected by most of the available assays, based 
on nucleic acid amplif﻿﻿ication. Several assays were developed to identify 
HCV genotypes and subtypes from the 5’ non-coding (NC) region because 
this region is readily amplif﻿﻿ied by PCR. However, this region does not 
contain suff﻿﻿icient information to resolve subtypes. Therefore, sequence 
analysis of the protein-coding regions such as Core, Envelope (E1) or 
nonstructural 5B (NS5B) of HCV genome are necessary to discriminating 
between subtypes8,14,22.
In Brazil, a country of continental dimensions, the distribution of 
HCV genotypes and subtypes among hemodialysis patients has not 
been well documented. Studies carried out in São Paulo15,16,19, Rio de 
Janeiro3, Belo Horizonte7, Recife1, Tocantins23, Goiás8 and Campo 
Grande10 have shown that genotype 1, subtype 1a, was prevalent in those 
patients. However, the genotyping methods employed in the majority of 
those studies (except in Goiás State), which were based on 5’ NC region 
analyses, did not permit the correct identif﻿﻿ication of the HCV subtypes. In 
the Federal District, Brazil, there are no data about the genetic diversity of 
HCV isolated in these patients. In the present study, the HCV genotypes 
and subtypes were determined in hemodialysis patients in the Federal 
District, Brazil, by nucleotide sequencing analysis of the 5’ NC and 
NS5B regions. 
MATERIALS AND METHODS
The study was carried out in the seven dialysis units of the Federal 
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District, Central Brazil. Between January and May 2002, blood samples 
were collected from 761 chronic hemodialysis patients (nearly 86% of 
this population) and serum samples were screened for anti-HCV by a 
third-generation enzyme-linked immunoassay (Abbott PrismR, Chicago, 
IL, USA). The study protocol was approved by the Ethics Committee 
of the Health Department of the Federal District, and written informed 
consent was obtained from each patient.
Sixty-six anti-HCV positive samples were subjected to RNA 
extraction by the commercially standardized reagents (QIAamp 
Viral RNA Mini Kit, Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions, followed by reverse transcription, as 
described by GINABREDA et al.11. cDNA was amplif﻿﻿ied using the 
primers complementary to the conserved area of the 5’ NC and NS5B 
regions and PCR conditions described by GINABREDA et al.11 and 
SANDRES-SAUNÉ et al.21, respectively. 
HCV genotyping was determined in HCV-RNA-positive samples 
by analyzing sequences of the 5’ NC and NS5B regions. The nested 
RT-PCR products were purif﻿﻿ied using the QIAquick gel extraction kit 
(Qiagen - GmbH, Hilden, Germany) and submitted to a direct nucleotide 
sequencing reaction using a Big Dye Terminator kit (version 3.1, 
Applied Biosystems, Foster City, CA, USA) and analyzed with the ABI 
3730 automated DNA sequencer. For 5’ NC region, the sequence from 
nucleotide 63 to nucleotide 316 was used for analysis and genotyping. 
For NS5B region, the sequence from nucleotide 8259 to nucleotide 8625 
was used for analysis, and genotyping was performed by phylogenetic 
analysis using reference sequences retrieved from GenBank. The 
homology among HCV sequences from the Federal District and those 
already deposited at HCV Databases was analyzed using the HCV-Blast 
program (available at http://hcv.lanl.gov). The phylogenetic tree was 
constructed with PHYLIP version 3.6 software9 using the neighbor-
joining method and the Kimura-two parameter, and its reliability was 
assessed by bootstrap resampling (1000 pseudo-replicas). To avoid 
cross-contamination between samples, standard precautions were used 
in all the manipulations. Separate areas were used for reagents, samples 
and manipulation of amplif﻿﻿ied products.
RESULTS AND DISCUSSION
The HCV RNA was detected in 51 samples by RT-nested PCR of 
the 5’NC region. Direct nucleotide sequencing of 207 nt from the 5’ 
NC region was performed in all HCV RNA-positive samples. Among 
them, 90.2% were of genotype 1, subtypes 1a (82.3%), 1b (5.9%) and 
1a/1b (2.0%). The remaining samples (9.8%) belonged to genotype 3, 
subtype 3a (Table 1).
Of the 51 HCV RNA-positive samples, 42 (82.3%) samples could be 
amplif﻿﻿ied and sequenced in the NS5B region. Using phylogenetic tree 
analysis of this region 328 nt, 38 sequences (90.5%) were classif﻿﻿ied as 
genotype 1, subtype 1a. All genotype 3 sequences (n = 4; 9.5%) were 
grouped inside the clad of subtype 3a of the phylogenetic tree (Fig. 1 
and Table 1).
For the 42 samples which were genotyped by sequencing of the two 
regions, the genotypes and subtypes determined were concordant in 100% 
and 95.2% of cases, respectively. Two samples showed discrepant results. 
These samples (subtype 1b by the analysis of the 5’ NC region) were 
identif﻿﻿ied as 1a by sequence analysis of the NS5B region. In addition, 
the 9 samples which were amplif﻿﻿ied and sequenced in the 5’NC region, 
but not in the NS5B region, were of subtype 1a (n = 6), 1b (n = 1), 1a/1b 
(n = 1) and 3a (n = 1). 
The distribution of HCV genotypes in the study population, with a 
predominance of subtype 1a (90.5%) followed by 3a (9.5%), differs from 
that of local blood donors, in which subtypes 3a (39.1%), 1a (34.1%) and 
1b (26.8%) were detected2. However, the predominance of genotype 1, 
subtype 1a was also found in other Brazilian studies carried out among 
hemodialysis patients1,8,10,15,16,19,23. These data suggest that the high 
frequency of subtype 1a is probably a consequence of HCV nosocomial 
transmission in hemodialysis units. 
In the present study, all 51 HCV RNA-positive samples were 
genotyped by sequence analysis of the 5’ NC region. Of these, 9 (17.7%) 
could not be genotyped by NS5B sequence analysis due to failure of the 
amplif﻿﻿ication procedure despite successive attempts to amplify cDNA 
with the NS5B primers. Although these primers are thought to bind highly 
conserved sequences21, primer-target mismatching within the NS5B 
region is still likely because the relative variability of its sequence that 
may not always be recognized by the used primers. Despite this inability 
to amplify all HCV RNA positive samples, NS5B sequence analysis was 
used here as a reference method for accurate genotyping8,21.
As observed by other authors6,8,12,18, no difference at the genotype 
level was found for the 42 samples that could be successfully amplif﻿﻿ied 
and sequenced in the the 5’ NC and NS5B regions. Also, in accordance 
with previous studies6,8,12,14,17,18,21, discrepant results at the subtype level, 
mainly subtypes 1a and 1b, were found here (two samples identif﻿﻿ied as 
1a by NS5B sequencing were subtyped as 1b by 5’ NC sequencing). 
Although both regions provide similar results at the genotype level, 
which is adequate for clinical practice, especially in the management of 
antiviral therapy, the NS5B sequencing appears to be more useful for 
epidemiological investigations. 
In conclusion, by means of 5’NC and NS5B sequence analysis, this 
study demonstrates that HCV subtype 1a is the most prevalent among 
hemodialysis patients in the Federal District, Brazil. In addition, the 
results presented here highlight that 5’ NC and NS5B regions provide 
Table 1
 Distribution of hepatitis C virus subtypes isolated from hemodialysis patients 
in the Federal District using the 5' noncoding (NC) and nonstructural 5B 
(NS5B) regions sequencing
Region/Subtype N Frequency (%)
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similar HCV genotyping results at the genotype level, which is adequate 
for clinical purposes, but direct sequencing of the NS5B region is more 
reliable for HCV subtype identif﻿﻿ication required in epidemiological 
studies.
RESUMO
Genótipos do vírus da hepatite C em pacientes em hemodiálise no 
Distrito Federal, Brasil
Os genótipos e subtipos do vírus da hepatite C (HCV) foram 
determinados em pacientes em hemodiálise no Distrito Federal, Brasil, 
pelo sequenciamento das regiões 5’ não codif﻿﻿icante (NC) e não estrutural 
5B (NS5B). De 761 pacientes, 66 amostras anti-HCV positivas foram 
testadas para RNA-HCV. Todas as 51 amostras RNA-HCV positivas 
por PCR para a região 5’ NC foram genotipadas como dos genótipos 1 
(90,2%) e 3 (9,8%). O subtipo 1a (82,3%) foi o mais prevalente, seguido 
pelos subtipos 3a (9,8%), 1b (5,9%) e 1a/1b (2,0%). Quarenta e duas 
amostras puderam ser amplif﻿﻿icadas e genotipadas na região NS5B: 38 
(90,5%) como genótipo 1, subtipo 1a, e 8 (9,5%) como genótipo 3, subtipo 
3a. Para as 42 amostras sequenciadas nas duas regiões, os genótipos e 
subtipos determinados foram concordantes em 100% e 95,2% dos casos, 
respectivamente. Duas amostras apresentaram resultados discrepantes, 
sendo que a região 5’ NC não diferenciou corretamente os subtipos 1a 
e 1b. Estes achados indicam que o genótipo 1, subtipo 1a, do HCV é o 
mais prevalente em pacientes em hemodiálise no Distrito Federal, Brasil.
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